Quick Dispatch:
Your soul trial oral semaglutide cardiovascular outcomes trial results Forecasting Trial Milestones: A Predictive Analysis for Early Termination of the SOUL Study | Diabetes Therapy orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your soul trial oral semaglutide cardiovascular outcomes trial results Forecasting Trial Milestones: A Predictive Analysis for Early Termination of the SOUL Study | Diabetes Therapy ships.
Need Help?
Questions about soul trial oral semaglutide cardiovascular outcomes trial results Forecasting Trial Milestones: A Predictive Analysis for Early Termination of the SOUL Study | Diabetes Therapy, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for soul trial oral semaglutide cardiovascular outcomes trial results Forecasting Trial Milestones: A Predictive Analysis for Early Termination of the SOUL Study | Diabetes Therapy in your area.
Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial
26.08
Impact of Oral Semaglutide on Kidney Outcomes in People With Type Diabetes: Results From the SOUL Randomized Trial
22.53
Forecasting Trial Milestones: A Predictive Analysis for Early Termination of the SOUL Study | Diabetes Therapy
29.61
At ADA 2025, the SOUL trial revealed that oral semaglutide (Rybelsus) reduced the risk of major cardiovascular events—like heart attack, stroke, and CV death—by 14% over ~4 years in type 2 diabetes
21.34
Congreso ACC. 25: Oral Semaglutide Reduces Cardiovascular Events in People With Type 2 Diabetes With Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial
20.06
SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes
20.70
In patients with cardiovascular disease and overweight or obesity but no diabetes, semaglutide was superior to placebo in lowering the risk of major adverse cardiovascular events at a mean follow-up of 39.8
26.33
